Longitudinal changes of CSF biomarkers in memory clinic patients

F. H. Bouwman*, W. M. Van Der Flier, N. S.M. Schoonenboom, E. J. Van Elk, A. Kok, F. Rijmen, M. A. Blankenstein, P. Scheltens

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


OBJECTIVE: In Alzheimer disease (AD), longitudinal changes of beta-amyloid1-42 (Aβ1-42), tau, and phosphorylated tau at threonine 181 (ptau-181) in CSF have been reported in small studies only. We evaluated the natural course of CSF biomarkers in patients with AD, subjective complaints, and mild cognitive impairment (MCI). METHODS: One hundred five patients (50 AD, 38 MCI, 17 subjective complaints) underwent two lumbar punctures, with a mean interval of 21 ± 9 months. CSF levels of Aβ1-42, tau, and ptau-181 were measured. RESULTS: CSF Aβ1-42 and tau levels showed main effects for both diagnosis and time (all p < 0.05), with average increases of 47 ± 72 and 49 ± 143 pg/mL. The interaction terms were not significant, which implies a similar time effect for all diagnostic groups. CSF ptau-181 levels showed a main effect for diagnosis (p = 0.01) but not for time (p = 0.27, increase of 1.0 ± 12 pg/mL). CONCLUSION: Levels of CSF beta-amyloid1-42 and tau but not phosphorylated tau at threonine 181 increased over time in this memory clinic patient cohort with comparable change in all diagnostic groups. The cross-sectional difference between diagnostic groups, however, exceeded by far the longitudinal changes within individuals, suggesting that these biomarkers are not sensitive as markers of disease progression.

Original languageEnglish
Pages (from-to)1006-1011
Number of pages6
Issue number10
Publication statusPublished - 1 Sep 2007

Cite this